| Literature DB >> 33367870 |
Cuicui Wang1, Wei Hao2, Ruihua Yu2, Xiaokang Wang2, Jing Zhang1, Bo Wang1.
Abstract
This study analyzed the pathogen distribution in bloodstream-infected (BSI) children hospitalized in Shandong Province from 2015 to 2018, to identify prevention strategies and select empiric antimicrobial therapy for BSI in children. Blood sample data from 14 107 children from 162 hospitals of Shandong Province were obtained from the China Antimicrobial Resistance Surveillance System and analyzed with WHONET 5.6 software. The results of the blood culture test showed the growth of 70.6% Gram-positive and 29.4% Gram-negative bacteria. Of the 14 107 blood isolates, 59.3% were collected from males and 40.7% were from females. Coagulase-negative staphylococci (47.1%) were the most commonly distributed pathogens. The distribution of pathogens varied according to age group and season. All Staphylococcus isolates were susceptible to vancomycin, teicoplanin and linezolid. Clinically, significant declines in penicillin-resistant Streptococcus pneumonia and carbapenem-resistant Escherichia coli were observed during the study period; however, detection rates of carbapenem-resistant Klebsiella pneumoniae increased over time (p < 0.05). Empiric antimicrobial therapy should be prescribed according to corresponding regional pediatric antimicrobial-resistant data.Entities:
Keywords: antimicrobial resistance; bloodstream infections; healthcare-associated infection; pediatric patients
Mesh:
Substances:
Year: 2021 PMID: 33367870 PMCID: PMC7948388 DOI: 10.1093/tropej/fmaa077
Source DB: PubMed Journal: J Trop Pediatr ISSN: 0142-6338 Impact factor: 1.165
Baseline patient characteristics
| Variable | HA-pediatric BSI* ( |
|---|---|
| Sex, | |
| Males | 8365 (59.3) |
| Females | 5742 (40.7) |
| Average age (years) | 1.82 |
| Age categories, | |
| −28 days | 4362 (30.9) |
| 29 days–1years | 5538 (39.3) |
| 1–2years | 998 (7.1) |
| 3–5years | 1561 (11.1) |
| 6–8years | 725 (5.1) |
| 9–11years | 521 (3.7) |
| 12–14years | 402 (2.8) |
| Hospitalization unit, | |
| General pediatric wards | 8312 (58.9) |
| Neonatal units | 3654 (25.9) |
| Intensive care unit | 1010 (7.2) |
| Pediatric surgery wards | 386 (2.7) |
| Others | 745 (5.3) |
| Patient's City, | |
| Jinnan | 2693 (19.1) |
| Linyi | 2521 (17.9) |
| Jining | 1435 (10.2) |
| Qingdao | 1359 (9.6) |
| Liaocheng | 919 (6.5) |
| Weifang | 815 (5.8) |
| Zaozhuang | 768 (5.4) |
| Binzhou | 728 (5.2) |
| Taian | 543 (3.8) |
| Rizhao | 531 (3.8) |
| Dongying | 445 (3.2) |
| Yantai | 415 (2.9) |
| Zibo | 368 (2.6) |
| Heze | 285 (2.0) |
| Weihai | 274 (1.9) |
| Dezhou | 69 (0.5) |
HA-pediatric BSI*, healthcare-associated pediatric bloodstream infection, aN = denominator used unless otherwise stated
Causative pathogens of healthcare-associated pediatric BSI in Shandong province
| Pathogen | HA-pediatric BSI* (% |
|---|---|
| Gram-positive | 9958 (70.6) |
| Coagulase-negative | 6648 (47.1) |
| | 992 (7.0) |
| | 55 (0.4) |
| | 828 (5.9) |
| | 352 (2.5) |
| | 314 (2.2) |
| | 267 (1.9) |
| | 29 (0.2) |
| | 18 (0.1) |
| | 625 (4.4) |
| | 384 (2.7) |
| | 197 (1.4) |
| | 63 (0.5) |
| | 25 (0.2) |
| Others | 56 (0.4) |
| Gram-negative | 4149 (29.4) |
| | 1173 (8.3) |
| | 790 (5.6) |
| | 719 (5.1) |
| | 63 (0.5) |
| | 325 (2.3) |
| | 319 (2.3) |
| | 248 (1.8) |
| | 274 (1.9) |
| | 267 (1.9) |
| | 234 (1.7) |
| | 135 (1.0) |
| | 50 (0.4) |
| | 38 (0.3) |
| | 34 (0.2) |
| | 17 (0.1) |
| | 16 (0.1) |
| | 15 (0.1) |
| | 15 (0.1) |
| | 15 (0.1) |
| | 14 (0.1) |
| | 13 (0.1) |
| | 13 (0.1) |
| Others | 144 (1.0) |
HA-pediatric BSI*, healthcare-associated pediatric bloodstream infection.
% of all pediatric BSIs (n/N), N = 14 107.
Fig. 1.(A) Percentage of main pathogens isolated at high frequency (>700 isolates totally) during 2015–2016 and 2017–2018. (B) Percentage of main pathogens isolated at intermediate frequency (200–700 isolates totally) during 2015–2016 and 2017–2018. Asterisks indicate statistical significance as p-values <0.05.
Fig. 2.Distribution of main pediatric BSIs pathogens with age (A–C) and season (D and E). (A) Gram-positive bacteria (group 1). (B) Gram-positive bacteria (group 2). (C) Gram-negative bacteria. (D) Percentage of main pathogens isolated at high frequency (>900 isolates totally) with season. (E) Percentage of main pathogens isolated at intermediate frequency (300–900 isolates totally) with season. Asterisks marked behind each species in (D) and (E) indicate statistical significance as p-values <0.05.
The AMR fluctuations in main pathogens from 2015–2016 to 2017–2018
| Pathogen | Antibiotic agent | Resistant rate (%) | Change (%) |
| ||
|---|---|---|---|---|---|---|
| Pooled | 2015–2016 | 2017–2018 | ||||
|
| PEN | 95.3 | 94.4 | 95.8 | 1.5 | 0.319 |
| OXA | 35.6 | 35.6 | 35.5 | −0.3 | 0.971 | |
| GEN | 15.4 | 17.6 | 14.0 | −20.5 | 0.146 | |
| RIF | 1.9 | 1.6 | 2.0 | 25.0 | 0.673 | |
| LVX | 7.7 | 8.7 | 6.9 | −20.7 | 0.328 | |
| SXT | 22.2 | 23.7 | 21.3 | −10.1 | 0.399 | |
| CLI | 58.7 | 60.9 | 57.4 | −5.7 | 0.301 | |
| ERY | 77.1 | 74.1 | 79.2 | 6.9 | 0.075 | |
| LNZ | 0.0 | 0.0 | 0.0 | 0.0 | – | |
| VAN | 0.0 | 0.0 | 0.0 | 0.0 | – | |
| TEC | 0.0 | 0.0 | 0.0 | 0.0 | – | |
| CoNS ( | PEN | 94.1 | 94.6 | 93.5 | −1.2 | 0.083 |
| OXA | 76.6 | 75.7 | 77.7 | 2.6 | 0.067 | |
| GEN | 18.5 | 17.7 | 19.4 | 9.6 | 0.095 | |
| RIF | 7.4 | 7.1 | 7.7 | 8.5 | 0.349 | |
| LVX | 28.3 | 27.9 | 28.9 | 3.6 | 0.383 | |
| SXT | 50.5 | 51.8 | 49.1 | −5.2 | 0.044 | |
| CLI | 48.2 | 47.9 | 48.5 | 1.3 | 0.642 | |
| ERY | 80.8 | 79 | 82.9 | 4.9 | 0.000 | |
| LNZ | 0.0 | 0.0 | 0.0 | 0.0 | – | |
| VAN | 0.0 | 0.0 | 0.0 | 0.0 | – | |
| TEC | 0.0 | 0.0 | 0.0 | 0.0 | – | |
|
| PEN | 4.0 | 6.6 | 2.4 | −63.6 | 0.008 |
| CRO | 5.1 | 7.9 | 3.5 | −55.7 | 0.029 | |
| LVX | 1.4 | 2.1 | 1.0 | −52.4 | 0.197 | |
| MFX | 0.5 | 0.0 | 0.7 | – | 0.356 | |
| SXT | 58.8 | 62.4 | 57.1 | −8.5 | 0.175 | |
| CLI | 92.5 | 90.4 | 93.7 | 3.7 | 0.190 | |
| ERY | 96.2 | 94.5 | 97.2 | 2.9 | 0.052 | |
| LNZ | 0.0 | 0.0 | 0.0 | 0.0 | – | |
| VAN | 0.0 | 0.0 | 0.0 | 0.0 | – | |
| CHL | 8.0 | 9.5 | 7.2 | −24.2 | 0.371 | |
| TCY | 68.1 | 83.5 | 86.0 | 3.0 | 0.390 | |
|
| PEN | 25.2 | 20.0 | 27.8 | 39.0 | 0.163 |
| CRO | 29.6 | 25.8 | 31.5 | 22.1 | 0.426 | |
| FEP | 19.1 | 21.1 | 18.1 | −14.2 | 0.648 | |
| LVX | 10.1 | 8.8 | 10.7 | 21.6 | 0.607 | |
| CLI | 60.4 | 46.4 | 68.4 | 47.4 | 0.000 | |
| ERY | 71.0 | 57.8 | 77.7 | 34.4 | 0.000 | |
| LNZ | 0.0 | 0.0 | 0.0 | 0.0 | – | |
| VAN | 0.0 | 0.0 | 0.0 | 0.0 | – | |
|
| PEN | 10.1 | 10.3 | 9.9 | −3.9 | 0.934 |
| AMP | 6.5 | 6.2 | 6.7 | 8.1 | 0.896 | |
| GEH | 27.8 | 38 | 20.4 | −46.3 | 0.012 | |
| CIP | 12.1 | 11.2 | 12.8 | 14.3 | 0.76 | |
| LVX | 8.1 | 8.5 | 7.8 | −8.2 | 0.876 | |
| ERY | 62.8 | 62.3 | 63.2 | 1.4 | 0.904 | |
| LNZ | 0.0 | 0.0 | 0.0 | 0.0 | – | |
| VAN | 0.0 | 0.0 | 0.0 | 0.0 | – | |
|
| PEN | 86.3 | 87.1 | 85.6 | −1.7 | 0.79 |
| AMP | 84.7 | 84.2 | 85.1 | 1.1 | 0.822 | |
| GEH | 37.6 | 49 | 28.2 | −42.4 | 0.000 | |
| CIP | 74.3 | 76.9 | 71.8 | −6.6 | 0.277 | |
| LVX | 55.7 | 59.6 | 52 | −12.8 | 0.147 | |
| ERY | 80.8 | 82.3 | 79.5 | −3.4 | 0.495 | |
| LNZ | 0.0 | 0.0 | 0.0 | 0.0 | – | |
| VAN | 0.0 | 0.0 | 0.0 | 0.0 | – | |
|
| AMP | 81.1 | 79.0 | 82.9 | 4.9 | 0.101 |
| CSL | 4.1 | 5.5 | 3.2 | −41.8 | 0.219 | |
| TZP | 2.9 | 4.8 | 1.3 | −72.9 | 0.001 | |
| CZO | 60.0 | 64.6 | 58.2 | −9.9 | 0.132 | |
| CXM | 49.5 | 49.0 | 49.7 | 1.4 | 0.885 | |
| CAZ | 16 | 16.6 | 15.5 | −6.6 | 0.621 | |
| CRO | 49.4 | 51 | 48.2 | −5.5 | 0.39 | |
| FEP | 16.3 | 15.6 | 16.8 | 7.7 | 0.587 | |
| FOX | 7.5 | 9.2 | 5.9 | −35.9 | 0.144 | |
| ATM | 26.4 | 26.4 | 26.3 | −0.4 | 0.968 | |
| IPM | 2.0 | 2.5 | 1.6 | −36.0 | 0.303 | |
| MEM | 2.6 | 3.7 | 1.7 | −54.1 | 0.113 | |
| AMK | 1.4 | 1.7 | 1.1 | −35.3 | 0.426 | |
| GEN | 40.5 | 42.8 | 38.6 | −9.8 | 0.159 | |
| CIP | 33.6 | 36.8 | 30.9 | −16.0 | 0.037 | |
| LVX | 32 | 35.5 | 29.0 | −18.3 | 0.02 | |
| SXT | 59.0 | 58.0 | 59.7 | 2.9 | 0.565 | |
|
| CSL | 14.6 | 9.9 | 17.0 | 71.7 | 0.117 |
| TZP | 16.2 | 10.9 | 20.9 | 91.7 | 0.000 | |
| CZO | 69.1 | 62.2 | 71.9 | 15.6 | 0.046 | |
| CXM | 69.0 | 66.9 | 70.0 | 4.6 | 0.553 | |
| CAZ | 38.4 | 39.2 | 37.7 | −3.8 | 0.702 | |
| CRO | 59.3 | 56.6 | 61.5 | 8.7 | 0.234 | |
| FEP | 34.9 | 24 | 42.9 | 78.8 | 0.000 | |
| FOX | 26.8 | 23.2 | 30.4 | 31.0 | 0.112 | |
| ATM | 41.8 | 32.7 | 48.0 | 46.8 | 0.000 | |
| IPM | 11.3 | 5.5 | 16.4 | 198.2 | 0.000 | |
| MEM | 10.9 | 7.7 | 13.4 | 74.0 | 0.076 | |
| AMK | 3.5 | 0.9 | 5.8 | 544.4 | 0.000 | |
| GEN | 29.2 | 30.3 | 28.2 | −6.9 | 0.526 | |
| CIP | 10.1 | 8.6 | 11.5 | 33.7 | 0.205 | |
| LVX | 6.1 | 3.3 | 8.8 | 166.7 | 0.003 | |
| SXT | 48.1 | 46.9 | 49.2 | 4.9 | 0.551 | |
|
| CSL | 6.9 | 10.8 | 2.9 | −73.1 | 0.358 |
| TZP | 10.4 | 11.9 | 9.2 | −22.7 | 0.55 | |
| CAZ | 30.7 | 41.7 | 22.0 | −47.2 | 0.007 | |
| CRO | 36.2 | 37.7 | 35.1 | −6.9 | 0.755 | |
| CTX | 35.3 | 38.1 | 33.3 | −12.6 | 0.726 | |
| FEP | 10.1 | 10.6 | 9.7 | −8.5 | 0.848 | |
| ATM | 30.1 | 34 | 27.8 | −18.2 | 0.436 | |
| IPM | 6.1 | 7.2 | 5.1 | −29.2 | 0.551 | |
| MEM | 6.2 | 8.6 | 3.6 | −58.1 | 0.105 | |
| AMK | 1.6 | 3.6 | 0.0 | −100.0 | 0.096 | |
| GEN | 11.8 | 13.6 | 10.3 | −24.3 | 0.501 | |
| CIP | 2.8 | 4.9 | 1.1 | −77.6 | 0.184 | |
| LVX | 2.8 | 6.0 | 0.0 | −100.0 | 0.021 | |
| SXT | 16.8 | 20.8 | 13.5 | −35.1 | 0.205 | |
|
| AMP | 58.5 | 56.0 | 61.2 | 9.3 | 0.412 |
| CRO | 13.9 | 19.2 | 9.8 | −49.0 | 0.070 | |
| FEP | 7.7 | 9.1 | 6.6 | −27.5 | 0.577 | |
| CIP | 18.5 | 20.4 | 15.8 | −22.5 | 0.577 | |
| LVX | 2.6 | 11.7 | 11.9 | 1.7 | 0.976 | |
| SXT | 13 | 8.9 | 17.1 | 92.1 | 0.055 | |
AMK, amikacin; AMP, ampicillin; ATM, aztreonam; CAZ, ceftazidime; CHL, chloramphenicol; CIP, ciprofloxacin; CLI, clindamycin; CRO, ceftriaxone; CSL, cefoperazone/sulbactam; CTX, cefotaxime; CXM, cefuroxime; CZO, cefazolin; ERY, erythromycin; FEP, cefepime; FOX, cefoxitin; GEH, gentamicin-high; GEN, gentamicin; IPM, imipenem; LNZ, linezolid; LVX, levofloxacin; MEM, meropenem; MFX, moxifloxacin; OXA, oxacillin; PEN, penicillin G; RIF, rifampin; SXT, trimethoprim/sulfamethoxazole; TCY, tetracycline; TEC, teicoplanin; TZP, piperacillin/tazobactam; VAN, vancomycin.
Difference of resistant rates between 2017–2018 and 2015–2016.
Statistical significance as p-values <0.05.